SPOTLIGHT
Leukemia taining remission if administered to P 190BCR-ABL -positive ALL patients, with long lasting control of the disease. 3 The efficacy of ␣-IFN as a front-line therapy in relapsed patients is still unknown. On the other hand, it has been recently reported that the combination of imatinib mesylate with ␣-IFN in proliferating assays in vitro (Bcr-Abl-positive cell lines and colony-forming assays generated from CML cells) has shown additive effects. 7 It is in particular noteworthy that all the patients whose samples were used in colony-forming assays had failed a trial of ␣-IFN alone, with perhaps an underestimation of the effects of the imatinib mesylate/␣-IFN combination.
Based on these biological and clinical premises, we successfully reinduced a complete morphological, cytogenetic and molecular remission in a P 190BCR-ABL+ patient who had previously proved sensitive to imatinib mesylate and ␣-IFN used as single agents, and had subsequently re-experienced a relapse to both drugs. The combination proved effective in a short period of time (49 days) and is to date (18 months) well tolerated. Interestingly, the qualitative PCR, that was persistently positive during the CR period induced by ␣-IFN, as well as during imatinib mesylate treatment, showed a negativization of the transcript during the combined treatment, starting from the first determination and persisting to date. Real time RT-PCR confirmed this result, showing a reduction of the number of copies of the bcr-abl fusion transcript during the combined treatment, well below the threshold line of the CML analyzed patients, 4 as well as of the data obtained during previous treatments in the same patient with ␣-IFN or imatinib mesylate as single treatment (Figure1). Thus, the combination not only proved effective in reinducing long-lasting continuous complete remission, but the quality of molecular remission was improved when compared to the previous treatments with single drugs, notwithstanding the more advanced state of the disease at the time of administration of the combination. Whether the biological and clinical effects of this combination are due to activation of different pathways, or to a reversal of the previous clinical resistance to each drug, is still unknown and worthy of investigation. It is interesting to note, however, that both drugs have been demonstrated to activate different apoptotic pathways in Ph + blastic crisis cell lines, namely Fas/Fasl and TRAIL induced by ␣-IFN and a direct apoptotic effect with imatinib mesylate, which could be possible reasons for their additive anti-leukemic effect. Further studies are warranted to elucidate the mechanism of this enhancement. Anyway, these data suggest that clinical trials with this combination are worth pursuing in patients with Ph + ALL, in particular if heavily pretreated, or with no available HLA compatible donor. TO THE EDITOR Imatinib mesylate (Glivec; Novartis, Basel, Switzerland) is a potent and selective inhibitor of the tyrosine kinase activity of BCR-ABL, which is a chimeric oncoprotein generated by reciprocal translocation between chromosomes 9 and 22 and implicated in the pathogenesis of Ph-positive leukemia.
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis
1,2 Based on the efficacy of imatinib mesylate in patients with chronic myeloid leukemia (CML) who are resistant to interferon, 3, 4 this drug is now widely used not only for Ph-positive CML but also for Ph-positive acute leukemia. 5 
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Figure 1
Time course of laboratory data before and after administration.of imatinib mesylate (a). A histological microphotogram of the liver biopsy (on 17th day after discontinuation of imatinib mesylate) showing focal necrosis of hepatocytes and infiltration of lymphocytes stained by the hematoxylin-eosin method (magnification, ×300) (b).
and ␥-GPT (21 U/l). On 12 February 2001, she complained of a generalized rash with fatigue, and laboratory examination at the time revealed elevated levels of GOT (220 U/l), GPT (342 U/l), LDH (919 U/l), ALP (435 U/l: normal range 71-231), ␥-GPT (185 U/l), LAP (221 U/l: normal range 35-75), total-bilirubin (3.78 mg/dl), direct-bilirubin (2.39 mg/dl), and amylase (439 mg/dl: normal range 70-243), whereas the levels of uric acid (2.4 mg/dl) and ionic phosphate (2.3 mg/dl) decreased. Her hematologic findings did not show remarkable change, including eosinophilia during and after imatinib mesylate treatment. No abnormalities were detected in the coagulation test and urinalysis. The echogram of the liver showed mild fatty liver, cholelithiasis, and mild splenomegaly, but there was no evidence of mechanical icterus by the cholelithiasis.
Based on the deterioration of biochemical data and her clinical manifestations, imatinib mesylate was discontinued after being administered for 11 days (total dose 400 mg × 11 days = 4400 mg). After discontinuation of imatinib mesylate, the laboratory data improved and her rash disappeared within 20 days (Figure 1a) . The maximum level of total-bilirubin was 4.56 mg/dl on the 3rd day of admission, whereas other biochemical data improved gradually. Drug lymphocyte-stimulating test (DLST) for imatinib mesylate was negative (110%) and viral analyses, including IgM-HA antibody, HBs-antigen, and HCV antibody, were all negative, and reactivation of ␤-herpesvirus, including CMV, EBV, HHV-6, HHV-7 and HHV-8, was not observed by PCR method (data not shown). We performed a liver biopsy on 28
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February 2002 (17th day after discontinuation of imatinib mesylate). Histological examination revealed focal necrosis of hepatocytes and mild infiltration of lymphocytes around necrosis lesions and on sinusoids of the liver ( Figure 1b) ; all these findings were compatible with those of the regression phase of acute viral hepatitis.
Although the adverse effects of imatinib mesylate are well known, 6, 7 the pathological examination of imatinib mesylate-induced hepatotoxicity has not been documented so far. The hepato-toxicity of imatinib mesylate that forced discontinuation of the administration is not clearly demonstrated. Talpaz found four of 50 CML patients who were treated with imatinib mesylate at a 400 mg dosage and one out of 50 CML patients at 800 mg dosage to show marked elevation of transaminases and bilirubin levels (maximum GPT of 2162 U/l; maximum total-bilirubin of 17.9 mg/dl), and administration of imatinib mesylate was completely stopped in two of five CML patients because of this adverse effect (Talpaz M, personal communication). In the present case, we could not find any evidence of hepatitis-inducible virus or reactivation of ␤-herpesvirus, and thus concluded that the hepato-toxicity exhibiting acute viral hepatitis-like histological features was induced by imatinib mesylate. Imatinib mesylate is metabolized by cytochrome P450 (CYP3A4) which exists in mitochondria in the liver, and thus other agents metabolized by cytochrome P450 may affect the concentration of imatinib mesylate. 8 However, the case presented here only received imatinib mesylate, therefore, we should pay close attention to this adverse but reversible effect of imatinib mesylate. 
